Bill Little

Bill Little is the current COO at Neovasc. Prior to this, they worked at Abbott from January 2012 to November 2019, where they held various positions including DVP Global Marketing, Head of Customer and New Market Insights, VP Global Cardiovascular Therapies, and VP Global Product Marketing. At Abbott, Bill was responsible for leading market development and share capture in global markets for innovative Cardiovascular and Neuromodulation devices. Bill also drove strategy and tactical execution in the Americas, Europe, Asia, and emerging markets, and managed $3B in annual revenue.

Some of Bill’s notable accomplishments at Abbott include transforming the Global Divisional Strategy for the $3B Abbott Vascular Business Unit, leading the St. Jude Medical integration team, and directing the global annual operating planning process. Bill also spearhead organization change management and cultural integration of the Vascular Division for the $30B St. Jude Medical / Abbott merger.

In their role as DVP Global Marketing, Head of Customer and New Market Insights at Abbott, Bill directed global structural heart and vascular marketing teams, including strategy & execution. Bill also led upstream marketing efforts for 70+ product lines representing $10B across all St, Jude Medical business units: Cardiac Rhythm Management, Cardiovascular, Electrophysiology, and Neuromodulation.

Bill Little received a Bachelor of Science in Business Administration with an emphasis in Marketing from the University of Colorado Boulder.

They are on a team with Shmuel Banai - Medical Director, Sarah Gallagher - VP, Clinical Affairs, and Lisa Becker - VP, Regulatory Affairs. Their manager is Fred Colen, President & CEO.